RBC Capital lowered the firm’s price target on Pliant Therapeutics to $50 from $53 and keeps an Outperform rating on the shares. The company’s bexo IPF program remains on track, with the phase 2b continuing to enroll, and while a clear path forward in the PSC- or primary sclerosing cholangitis – indication remains unknown until the FDA meeting mid-year, the upcoming 24-week PSC data should further support bexo’s clinical profile and safety, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PLRX:
- 3 Best Stocks to Buy Now, 2/28/2024, According to Top Analysts
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
- Pliant Therapeutics price target lowered to $43 from $48 at Canaccord
- Pliant Therapeutics price target lowered to $47 from $49 at Oppenheimer
- Pliant Therapeutics Achieves Success in Liver Disease Trial